{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:18:43Z","timestamp":1790399923656,"version":"4.1.0"},"reference-count":126,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Chemokine receptor CXCR4 is overexpressed in neoplasms and its expression is related to tumour invasion, metastasis and aggressiveness. 68Ga-Pentixafor is used to non-invasively image the expression of CXCR4 in tumours and has been widely used in haematological malignancies. Recent evidence shows that therapies targeting CXCR4 can increase the chemosensitivity of the tumour as well as inhibit tumour metastasis and aggressiveness. 68Ga-Pentixafor has shown promise as an elegant radiotracer to aid in the selection of patients whose tumours demonstrate CXCR4 overexpression and who therefore may benefit from novel therapies targeting CXCR4. In addition, its therapeutic partners 177Lu- and 90Y-Pentixather have been investigated in the treatment of patients with advanced haematological malignancies, and initial studies have shown a good treatment response in metabolically active lesions. 68Ga-Pentixafor in solid tumours complements 18F-FDG by providing prognostic information and selecting patients who may benefit from therapies targeting CXCR4. This review summarises the available literature on the potential applications of 68Ga-Pentixafor in solid tumours.<\/jats:p>","DOI":"10.3390\/diagnostics12092135","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T23:35:57Z","timestamp":1662420957000},"page":"2135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Current Status of 68Ga-Pentixafor in Solid Tumours"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2322-9452","authenticated-orcid":false,"given":"Bawinile","family":"Hadebe","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa"},{"name":"Inkosi Albert Luthuli Central Hospital, Durban 4058, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2806-0625","authenticated-orcid":false,"given":"Machaba Michael","family":"Sathekge","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Aldous","sequence":"additional","affiliation":[{"name":"Department of Genetics, College of Health Sciences, University of KwaZulu Natal, Durban 4058, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-1553","authenticated-orcid":false,"given":"Mariza","family":"Vorster","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa"},{"name":"Inkosi Albert Luthuli Central Hospital, Durban 4058, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5483\/BMBRep.2014.47.1.069","article-title":"Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer","volume":"47","author":"Li","year":"2014","journal-title":"BMB Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.21037\/tcr-21-1561","article-title":"Pan-cancer analysis of CXCR4 carcinogenesis in human tumors","volume":"10","author":"Wang","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_3","first-page":"175","article-title":"Molecular Imaging in Oncology Using Positron Emission Tomography","volume":"115","author":"Derlin","year":"2018","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000455706","article-title":"CXCR4: A New Player in an Old Scene?","volume":"79","author":"Knopf","year":"2017","journal-title":"ORL J. Otorhinolaryngol. Relat. Spec."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41181-020-0091-2","article-title":"Fully-automated production of [(68)Ga]Ga-PentixaFor on the module Modular Lab-PharmTracer","volume":"5","author":"Spreckelmeyer","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-019-0983-5","article-title":"Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: A systematic review","volume":"18","author":"Peltanova","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"591386","DOI":"10.3389\/fonc.2021.591386","article-title":"CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment","volume":"11","author":"Santagata","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/pros.21008","article-title":"Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth","volume":"69","author":"Porvasnik","year":"2009","journal-title":"Prostate"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Caspa Gokulan, R., and Devaraj, H. (2021). Stem Cell Markers CXCR-4 and CD133 Predict Aggressive Phenotype and Their Double Positivity Indicates Poor Prognosis of Oral Squamous Cell Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13235895"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8938","DOI":"10.1158\/0008-5472.CAN-08-2155","article-title":"Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells","volume":"68","author":"Sung","year":"2008","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bbamem.2006.11.002","article-title":"Regulation of CXCR4 signaling","volume":"1768","author":"Busillo","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"110093","DOI":"10.1016\/j.cellsig.2021.110093","article-title":"SOX17 inhibits proliferation and invasion of neuroblastoma through CXCL12\/CXCR4 signaling axis","volume":"87","author":"Wang","year":"2021","journal-title":"Cell. Signal."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/JLB.5BT1219-714R","article-title":"At the bedside: Profiling and treating patients with CXCR4-expressing cancers","volume":"109","author":"Martin","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1021\/acs.molpharmaceut.9b00069","article-title":"Development and Evaluation of an (18)F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 Expression","volume":"16","author":"Brickute","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41388-018-0452-4","article-title":"A feed-forward loop between nuclear translocation of CXCR4 and HIF-1\u03b1 promotes renal cell carcinoma metastasis","volume":"38","author":"Bao","year":"2019","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/bjc.2012.110","article-title":"CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients","volume":"106","author":"Schrevel","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13550-018-0442-0","article-title":"PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma","volume":"8","author":"Vag","year":"2018","journal-title":"EJNMMI Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1128\/JVI.75.12.5457-5464.2001","article-title":"Cooperation of the V1\/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor","volume":"75","author":"Labrosse","year":"2001","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1073\/pnas.94.5.1925","article-title":"The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes","volume":"94","author":"Bleul","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cmdc.201100320","article-title":"PET imaging of CXCR4 receptors in cancer by a new optimized ligand","volume":"6","author":"Demmer","year":"2011","journal-title":"ChemMedChem"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00259-021-05196-4","article-title":"CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [(68)Ga]Ga-Pentixafor \/[(177)Lu]Lu-Pentixather","volume":"49","author":"Jacobs","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","first-page":"1","article-title":"CXCR4-targeted theranostics in oncology","volume":"8","author":"Buck","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11307-022-01717-1","article-title":"Impact of tumor burden on normal organ distribution in patients imaged with CXCR4-targeted [68Ga] Ga-PentixaFor PET\/CT","volume":"24","author":"Serfling","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","article-title":"The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: Implications for peptide receptor radionuclide therapy","volume":"39","author":"Beauregard","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2967\/jnumed.115.161034","article-title":"First experience with chemokine receptor CXCR4\u2013targeted PET imaging of patients with solid cancers","volume":"57","author":"Vag","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.coms.2018.06.001","article-title":"Epidemiology and Demographics of the Head and Neck Cancer Population","volume":"30","author":"Cohen","year":"2018","journal-title":"Oral Maxillofac. Surg. Clin. N. Am."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"vi7","DOI":"10.1093\/annonc\/mdi452","article-title":"Current clinical outcomes demand new treatment options for SCCHN","volume":"16","author":"Lefebvre","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejca.2017.01.018","article-title":"A PET-based nomogram for oropharyngeal cancers","volume":"75","author":"Castelli","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1586\/14737140.6.7.1111","article-title":"Head and neck cancer: Past, present and future","volume":"6","author":"Chin","year":"2006","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1258\/ebm.2011.010389","article-title":"Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases","volume":"236","author":"Choi","year":"2011","journal-title":"Exp. Biol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8169","DOI":"10.1007\/s13277-015-4686-2","article-title":"Inflammatory CXCL12-CXCR4\/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells","volume":"37","author":"Qiao","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014\u20132018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_37","first-page":"665","article-title":"Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: An accelerated growth factor in glioblastomas","volume":"34","author":"Komatani","year":"2009","journal-title":"Int. J. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1227\/01.NEU.0000324896.26088.EF","article-title":"CXCR4 Expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities","volume":"63","author":"Stevenson","year":"2008","journal-title":"Neurosurgery"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1010428317695528","DOI":"10.1177\/1010428317695528","article-title":"The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models","volume":"39","author":"Gravina","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.3748\/wjg.v21.i26.7933","article-title":"Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries","volume":"21","author":"Arnal","year":"2015","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/jnci\/dji431","article-title":"ARTICLES Tumor-Cell Homing to Lymph Nodes and Bone Marrow and CXCR4 Expression in Esophageal Cancer","volume":"97","author":"Kaifi","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1007\/s13277-013-1490-8","article-title":"Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: A meta-analysis","volume":"35","author":"Wu","year":"2014","journal-title":"Tumor Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1245\/s10434-015-4974-5","article-title":"CXCR4 Expression is Associated with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma","volume":"24","author":"Goto","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"152787","DOI":"10.1016\/j.prp.2019.152787","article-title":"Clinicopathologic significance of CXCR4 expressions in patients with esophageal squamous cell carcinoma","volume":"216","author":"Yang","year":"2020","journal-title":"Pathol.-Res. Pract."},{"key":"ref_45","first-page":"635","article-title":"First clinical experience with [68] Ga-Pentixafor PET\/CT in esophageal cancer","volume":"56","author":"Kobe","year":"2015","journal-title":"Soc. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40644-021-00391-w","article-title":"Pentixafor PET\/CT for imaging of chemokine receptor 4 expression in esophageal cancer\u2014A first clinical approach","volume":"21","author":"Linde","year":"2021","journal-title":"Cancer Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Weich, A., Werner, R.A., Buck, A.K., Hartrampf, P.E., Serfling, S.E., Scheurlen, M., Wester, H.-J., Meining, A., Kircher, S., and Higuchi, T. (2021). CXCR4-Directed PET\/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040605"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7150\/thno.18754","article-title":"Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors\u2014A Triple Tracer Comparative Approach","volume":"7","author":"Werner","year":"2017","journal-title":"Theranostics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9288","DOI":"10.18632\/oncotarget.7063","article-title":"[68Ga] Pentixafor-PET\/CT for imaging of chemokine receptor 4 expression in small cell lung cancer-initial experience","volume":"7","author":"Lapa","year":"2016","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.18632\/oncotarget.3242","article-title":"Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms","volume":"6","author":"Kaemmerer","year":"2015","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00259-017-3622-7","article-title":"68Ga-Pentixafor PET\/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant","volume":"44","author":"Watts","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/path.2829","article-title":"The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma","volume":"223","author":"Li","year":"2011","journal-title":"J. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"96732","DOI":"10.18632\/oncotarget.18235","article-title":"Targeting CXCR4 with [(68)Ga]Pentixafor: A suitable theranostic approach in pleural mesothelioma?","volume":"8","author":"Lapa","year":"2017","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.febslet.2012.08.011","article-title":"Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016","volume":"586","author":"Otani","year":"2012","journal-title":"FEBS Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100239","DOI":"10.1016\/j.jbo.2019.100239","article-title":"CXCR4 in human osteosarcoma malignant progression. The response of osteosarcoma cell lines to the fully human CXCR4 antibody MDX1338","volume":"17","author":"Pollino","year":"2019","journal-title":"J. Bone Oncol."},{"key":"ref_56","first-page":"863","article-title":"Expression of CXCR4 and MMP-2 is associated with poor prognosis in patients with osteosarcoma","volume":"35","author":"Gong","year":"2020","journal-title":"Histol. Histopathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s11904-012-0128-6","article-title":"Human papillomavirus vaccines: Where do they fit in HIV-infected individuals?","volume":"9","author":"Firnhaber","year":"2012","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jclinpath-2020-206917","article-title":"CXCR4\/ACKR3\/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma","volume":"75","author":"Rusetska","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/IGC.0b013e3182958f95","article-title":"Association of CXC chemokine receptor type 4 expression and clinicopathologic features in human vulvar cancer","volume":"23","author":"Shiozaki","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_60","first-page":"6643782","article-title":"The value and clinical significance of tumor marker detection in cervical cancer","volume":"2021","author":"Sun","year":"2021","journal-title":"Sci. Program."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Oany, A.R., Mia, M., Pervin, T., Alyami, S.A., and Moni, M.A. (2021). Integrative Systems Biology Approaches to Identify Potential Biomarkers and Pathways of Cervical Cancer. J. Pers. Med., 11.","DOI":"10.20944\/preprints202103.0197.v1"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejogrb.2017.04.043","article-title":"Association of CXCR4, CCR7, VEGF-C and VEGF-D expression with lymph node metastasis in patients with cervical cancer","volume":"214","author":"Dai","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/CEJ.0000000000000597","article-title":"Ovarian cancer risk in relation to blood lipid levels and hyperlipidemia: A systematic review and meta-analysis of observational epidemiologic studies","volume":"30","author":"Zhang","year":"2021","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Liu, C.-F., Liu, S.-Y., Min, X.-Y., Ji, Y.-Y., Wang, N., Liu, D., Ma, N., Li, Z.-F., and Li, K. (2014). The prognostic value of CXCR4 in ovarian cancer: A meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092629"},{"key":"ref_65","first-page":"5930","article-title":"Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer","volume":"62","author":"Scotton","year":"2002","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., and Stanis\u0142awek, A. (2021). Breast Cancer\u2014Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies\u2014An Updated Review. Cancers, 13.","DOI":"10.3390\/cancers13174287"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jconrel.2021.12.026","article-title":"\u201cAttractive\/adhesion force\u201d dual-regulatory nanogels capable of CXCR4 antagonism and autophagy inhibition for the treatment of metastatic breast cancer","volume":"341","author":"Dong","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41420-021-00508-x","article-title":"ETV4 promotes breast cancer cell stemness by activating glycolysis and CXCR4-mediated sonic Hedgehog signaling","volume":"7","author":"Zhu","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_69","first-page":"46","article-title":"The Role of chemokine receptor CXCR4 in breast cancer metastasis","volume":"3","author":"Mukherjee","year":"2013","journal-title":"Am. J. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1038\/35065016","article-title":"Involvement of chemokine receptors in breast cancer metastasis","volume":"410","author":"Muller","year":"2001","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Ni, C., Chen, W., Wu, P., Wang, Z., Yin, J., Huang, J., and Qiu, F. (2014). Expression of CXCR4 and breast cancer prognosis: A systematic review and meta-analysis. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-49"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.canep.2013.04.017","article-title":"The impact of chemokine receptor CXCR4 on breast cancer prognosis: A meta-analysis","volume":"37","author":"Xu","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"ref_73","first-page":"4953","article-title":"CXCR4 in breast cancer: Oncogenic role and therapeutic targeting","volume":"9","author":"Xu","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/bjc.2014.1","article-title":"Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer","volume":"110","author":"Yang","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Vorster, M., and Sathekge, M.M. (2021). Theranostics in Metastatic Castrate Resistant Prostate Cancer, Exon Publications.","DOI":"10.36255\/exonpublications.prostatecancer.theranostics.2021"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"95606","DOI":"10.18632\/oncotarget.21024","article-title":"[(68)Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model\u2014Comparison with [(18)F]FDG PET\/CT, MRI and ex vivo receptor expression","volume":"8","author":"Stenzel","year":"2017","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3389\/fonc.2019.00503","article-title":"[(68)Ga]-Pentixafor PET\/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas","volume":"9","author":"Breun","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJMra2020394","article-title":"Vestibular schwannomas","volume":"384","author":"Carlson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9940","DOI":"10.18632\/oncotarget.24119","article-title":"CXCR4: A new player in vestibular schwannoma pathogenesis","volume":"9","author":"Breun","year":"2018","journal-title":"Oncotarget"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41416-021-01513-8","article-title":"Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: A cohort study","volume":"125","author":"Kimpel","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"597878","DOI":"10.3389\/fendo.2020.597878","article-title":"Impact of the chemokine receptors CXCR4 and CXCR7 on clinical outcome in adrenocortical carcinoma","volume":"11","author":"Chifu","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_83","first-page":"OP1_01","article-title":"A novel theranostic concept for adrenocortical neoplasia targeting the chemokine receptor CXCR4","volume":"123","author":"Heinze","year":"2015","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_84","first-page":"e29","article-title":"Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using (68)Ga-PentixaFor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_85","first-page":"145","article-title":"A theranostic approach for adrenocortical neoplasia based on high adrenal CXCR4 expression","volume":"56","author":"Bluemel","year":"2015","journal-title":"Soc. Nucl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/RLU.0000000000001435","article-title":"Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients","volume":"42","author":"Bluemel","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semcancer.2019.12.007","article-title":"The CXCL12-CXCR4\/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies","volume":"65","author":"Daniel","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/PAI.0000000000000828","article-title":"Prognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients","volume":"28","author":"Ottaiano","year":"2020","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/1354750X.2019.1637941","article-title":"CXCR4 as a prognostic biomarker in gastrointestinal cancer: A meta-analysis","volume":"24","author":"Jiang","year":"2019","journal-title":"Biomarkers"},{"key":"ref_90","unstructured":"Ahern, E., Thomas, P., Campbell, L., Latter, M., Eastgate, M., Wyld, D., Clark, D.A., Stevenson, A.R., O\u2019Rourke, N., and Cavallucci, D. (2022, June 11). Pentixafor as a Theranostic Agent in Rectal and Pancreatic Adenocarcinoma: Outcomes from a Pilot Study. Available online: https:\/\/assets.researchsquare.com\/files\/rs-1274952\/v2\/a428a666-268f-4ecb-ab7b-775009d7d389.pdf?c=1650455491."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"102055","DOI":"10.1016\/j.canep.2021.102055","article-title":"Maternal lifestyle factors and risk of neuroblastoma in the offspring: A meta-analysis including Greek NARECHEM-ST primary data","volume":"77","author":"Karalexi","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"ref_92","first-page":"330","article-title":"The management and outcomes of neuroblastoma in South African children","volume":"23","year":"2021","journal-title":"Belg. J. Paediatr."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Quinn, C.H., Beierle, A.M., and Beierle, E.A. (2021). Artificial Tumor Microenvironments in Neuroblastoma. Cancers, 13.","DOI":"10.3390\/cancers13071629"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Liberman, J., Sartelet, H., Flahaut, M., M\u00fchlethaler-Mottet, A., Coulon, A., Nyalendo, C., Vassal, G., Joseph, J.M., and Gross, N. (2012). Involvement of the CXCR7\/CXCR4\/CXCL12 axis in the malignant progression of human neuroblastoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043665"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.21037\/jgo.2020.02.08","article-title":"Addressing the worldwide hepatocellular carcinoma: Epidemiology, prevention and management","volume":"12","author":"Samant","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/cmi.2008.46","article-title":"Roles of Chemokine Receptor 4 (CXCR4) and Chemokine Ligand 12 (CXCL12) in Metastasis of Hepatocellular Carcinoma Cells","volume":"5","author":"Liu","year":"2008","journal-title":"Cell. Mol. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3389\/fonc.2019.00770","article-title":"CXCR4-Directed Imaging in Solid Tumors","volume":"9","author":"Werner","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_99","unstructured":"Huang, S., Wang, G., Kou, M., Huang, Y., Yanhong, H., Yunpeng, B., Yingbang, L., and Huang, W. (2022, June 12). The Therapeutic and Prognostic Value of Chemokine Receptors (CXCRs) in Skin Cutaneous Melanoma (SKCM) Progression. Available online: https:\/\/assets.researchsquare.com\/files\/rs-618975\/v1\/5863050f-b9f2-4c8e-a64b-b8944e2e167c.pdf?c=1631884921."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Soltantoyeh, T., Akbari, B., Karimi, A., Mahmoodi Chalbatani, G., Ghahri-Saremi, N., Hadjati, J., Hamblin, M.R., and Mirzaei, H.R. (2021). Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead. Cells, 10.","DOI":"10.3390\/cells10061450"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1158\/1078-0432.CCR-18-1368","article-title":"Arylsulfonamide 64B inhibits hypoxia\/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma","volume":"25","author":"Dong","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"155691","DOI":"10.1016\/j.cyto.2021.155691","article-title":"Overexpression of chemokine receptor CXCR4 predicts lymph node metastatic risk in patients with melanoma: A systematic review and meta-analysis","volume":"148","author":"Alimohammadi","year":"2021","journal-title":"Cytokine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13244-021-01147-7","article-title":"Multimodal molecular imaging evaluation for early diagnosis and prognosis of cholangiocarcinoma","volume":"13","author":"Liu","year":"2022","journal-title":"Insights Imaging"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4251\/wjgo.v13.i10.1336","article-title":"Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"13","author":"Saffioti","year":"2021","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_105","first-page":"1","article-title":"An Insight into Cholangiocarcinoma and Recent Advances in its Treatment","volume":"13","author":"Sahu","year":"2022","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3892\/ol.2013.1587","article-title":"CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1\/2","volume":"6","author":"Leelawat","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13046-014-0103-8","article-title":"Blockade of CXCL12\/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway","volume":"33","author":"Zhao","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5009\/gnl.2014.8.2.196","article-title":"Silencing of CXCR4 inhibits tumor cell proliferation and neural invasion in human hilar cholangiocarcinoma","volume":"8","author":"Tan","year":"2014","journal-title":"Gut Liver"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Krieg, A., Riemer, J.C., Telan, L.A., Gabbert, H.E., and Knoefel, W.T. (2015). CXCR4-A prognostic and clinicopathological biomarker for pancreatic ductal adenocarcinoma: A Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130192"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijsu.2019.03.009","article-title":"Clinicopathological significance and prognostic role of chemokine receptor CXCR4 expression in pancreatic ductal adenocarcinoma, a meta-analysis and literature review","volume":"65","author":"Ding","year":"2019","journal-title":"Int. J. Surg."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fonc.2019.00490","article-title":"Targeting the tumor microenvironment in renal cell cancer biology and therapy","volume":"9","author":"Heidegger","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijsu.2019.08.021","article-title":"Clinicopathological and prognostic significance of CXCR4 high expression in renal cell carcinoma: A meta-analysis and literature review","volume":"71","author":"Si","year":"2019","journal-title":"Int. J. Surg."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-5-56","article-title":"Stromal derived factor-1 (SDF-1\/CXCL12) and CXCR4 in renal cell carcinoma metastasis","volume":"5","author":"Pan","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Machlowska, J., Baj, J., Sitarz, M., Maciejewski, R., and Sitarz, R. (2020). Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21114012"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","article-title":"Burden of gastric cancer","volume":"18","author":"Thrift","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_117","first-page":"473","article-title":"Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer","volume":"34","author":"Lee","year":"2009","journal-title":"Int. J. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1038\/s41598-022-08622-1","article-title":"Characteristics of immunophenotypes and immunological in tumor microenvironment and analysis of immune implication of CXCR4 in gastric cancer","volume":"12","author":"Wen","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1158\/0008-5472.CAN-05-3393","article-title":"Role of the CXCL12\/CXCR4 axis in peritoneal carcinomatosis of gastric cancer","volume":"66","author":"Yasumoto","year":"2006","journal-title":"Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/thno.5376","article-title":"Small molecule inhibitors of CXCR4","volume":"3","author":"Debnath","year":"2013","journal-title":"Theranostics"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e2015433118","DOI":"10.1073\/pnas.2015433118","article-title":"A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment","volume":"118","author":"Song","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s12149-018-1290-8","article-title":"CXCR4-directed theranostics in oncology and inflammation","volume":"32","author":"Kircher","year":"2018","journal-title":"Ann. Nucl. Med."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Ling, X., Spaeth, E., Chen, Y., Shi, Y., Zhang, W., Schober, W., Hail, N., Konopleva, M., and Andreeff, M. (2013). The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058426"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2967\/jnumed.118.223420","article-title":"Side effects of CXC-chemokine receptor 4\u2013directed endoradiotherapy with pentixather before hematopoietic stem cell transplantation","volume":"60","author":"Maurer","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2967\/jnumed.118.210997","article-title":"Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma","volume":"60","author":"Lapa","year":"2019","journal-title":"J. Nucl. Med."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/9\/2135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:22:32Z","timestamp":1760142152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/9\/2135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":126,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["diagnostics12092135"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12092135","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}